What You Should Know:
- myTomorrows, a global health technology company connecting patients with all possible treatment options, today announced a new partnership with brainstrust, a UK-based charity that helps people living with a brain tumor reach their potential and thrive.
- Under the new partnership, people with brain tumors will be equipped with the means to bolster their knowledge of relevant treatment options, potentially extending to participation in clinical trials and access to pre-approval drugs. Moreover, the partnership provides a new layer of support to clinicians in their efforts to recruit patients to relevant clinical trials.
Empowering Brain Tumor Patients: Accessing Clinical Trials and Expert Support
In England alone, there are 80,000 individuals grappling with a brain tumor, and a new diagnosis occurs every two hours. Brain tumors claim the lives of more individuals under 40 than any other cancer, and both occurrences and fatalities related to these tumors are increasing.
With a mere 12% of brain tumor patients surviving beyond five years post-diagnosis, it becomes imperative to equip these patients with comprehensive and accurate information, particularly concerning clinical trials. Locating and comprehending pertinent details about such trials often poses a challenge.
brainstrust will now furnish its extensive patient network with timely and relevant information on credible and accessible clinical trials, thanks to the collaboration with myTomorrows. Through the assistance of myTomorrows’ trained patient navigators, individuals affected by brain tumors, along with their families and healthcare providers, will have a dedicated point of contact. These navigators will steer them through the complex landscape of medical options and aid in making informed decisions throughout their treatment journey.
“We are very excited to be partnering with brainstrust, which boasts years of experience supporting and educating patients with brain cancer about many different aspects of their disease. Our collaboration aims to empower these patients to navigate their treatment journeys with more confidence and options,” said Michel van Harten, CEO of myTomorrows. “Collaborating with leading patient advocacy organizations like brainstrust allows myTomorrows to extend our reach to patients affected by numerous conditions. This partnership forms part of our overall mission to raise patients’ and physicians’ awareness of different treatment options while enabling pharmaceutical companies to expand access throughout the drug development cycle.”
